Multi-Center, Double-Blind Clinical Study Validates DefenAge® as a Best-in-Class Anti-Aging Solution, Naturally Turning Back the Clock
Progenitor Biologics® , LLC, the manufacturer and distributor of the cutting-edge anti-aging skin care products, DefenAge ® Skincare, is proud to announce the results of a new comprehensive clinical study of the line’s breakthrough ingredient Age-Repair Defensins ® . The defensin -based three-step system “globally improves the visual appearance of aging skin without irritation, dryness, or inflammation,” concludes the peer-review article published by the Journal of Drugs in Dermatology (JDD). Target-specific Age-Repair Defensins represents the latest generation of anti-aging technology and is the FIRST of a kind.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180402005989/en/
“The defensin skin care regimen resulted in statistically significant improvements in ALL five parameters in patients simultaneously including decreased visible fine and coarse wrinkles, pore size and visible pigmentation. Study participants also demonstrated improvement in skin’s oiliness, evenness, hydration and a number of other crucial skin’s qualities” shares the study’s principal investigator and correspondence author, Amy Forman Taub, MD. “DefenAge results in profound improvements in the visible health and beauty of the skin that are readily apparent to even the untrained eye.”
“The results showed that the defensin -containing trio of products offer most of the advantages of time-honored retinols as well as newer but widely used growth-factor containing cosmeceuticals, without irritation or inflammation, sun-sensitivity, or concerns about neoplasia of the treated skin,” adds the study’s co-investigator, Vivian Bucay, MD. “The observed clinical results put DefenAge Skincare into the best-in-class category without doubt, this is a landmark product.”
The earlier-published pre-clinical research shows that defensins activate dormant preserve of “fresh” cells in the body, LGR6-positive stem cells. “After activation, LGR6-positive stem cells physically migrate into the basal layer of the skin and create a new epidermis, and eventually, new, younger-acting skin,” explains the study’s co-investigator, Gregory Keller, MD. “The defensin -based anti-aging technology is an authentic paradigm shift that I see only once per decade.”
“DefenAge made an initial soft launch in the summer of 2015,” comments Progenitor Biologics’ CEO, Nikolay Turovets, PhD. “Today, more than 300 US-based aesthetic physicians and medi-spas offer DefenAge . Since the launch, DefenAge’s annual growth exceeded 100 percent three years in a row, having sales in 2017 that exceeded $2.4M. Now having such solid clinical proof of the product’s performance, we will continue our expansion in the aesthetic market and deliver the best technologies to consumers.”
The study was conducted by Amy Forman Taub, MD, Vivian Bucay, MD, Gregory Keller, MD, Jay Williams, PhD, and Darius Mehregan, MD. A participant- and investigator -blinded, placebo-controlled, multi-center trial was performed in outpatient settings on forty-four female subjects, 41-71 years old, skin types I-V. The evaluation was performed at baseline, 6 and 12 weeks. The DefenAge 3-step system (trade name: Clinical Power Trio) includes: 2-Minute Reveal Masque, 24/7 Barrier Balance Cream and 8-in-1 BioSerum. The peer-review article is entitled: ”Multi-center, double-blind, vehicle-controlled clinical trial of an alpha and beta defensin -containing anti-aging skin care regimen with clinical, histopathologic, immunohistochemical, photographic, and ultrasound evaluation” [Taub A, et al. J Drugs Dermatol. 2018 Apr;17(4):426-441].
Read the full-text article in the JDD April 2018 issue: http://jddonline.com/articles/dermatology/S1545961618P0426X
DefenAge ® Skincare is a technology-driven anti-aging skin care line, primarily distributed through the professional aesthetic market including dermatology and aesthetic surgery practices. The key ingredient, Age-Repair Defensins ® , features a stand-alone natural target-specific mechanism of action. The technology is patent-pending, exclusively available in DefenAge and does not belong to the growth factor category. The Clinical Power Trio is clinical study tested, DefenAge’s core skin care regimen that addresses visible signs of skin aging on a global scale. DefenAge products do not contain: animal- or human- originated ingredients, parabens, formaldehyde-releasing preservatives, sulfates, mineral oils, colorants, phthalates or BPA.
The products are available at www.DefenAge.com .
For more information, please visit www.DefenAge.com
or connect with the company on
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
IL-FRISS19.11.2018 14:02 | pressemeddelelse
FRISS: Insurance Carriers Prioritize Fraud Detection and Prevention
BOC-GROUP19.11.2018 13:06 | pressemeddelelse
BOC Group´s ADOIT Receives the Highest Score in “Rearchitecting the Enterprise for Transformation” Use Case in Gartner’s 2018 Critical Capabilities for Enterprise Architecture Tools
CENTRAIR19.11.2018 12:21 | pressemeddelelse
Chubu Centrair International Airport Has Been Ranked 5-Star Airport for Second Time
PA-BLOMMER-CHOCOLATE19.11.2018 10:05 | pressemeddelelse
Blommer Chocolate to Be Acquired by Fuji Oil Holding
GSMA19.11.2018 10:02 | pressemeddelelse
GSMA Announces New Speakers for Mobile 360 Series – MENA
DC-DENTONS19.11.2018 09:02 | pressemeddelelse
Dentons Global Chairman and Global Chief Executive Officer Re-Elected
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum